Who Exports Ramipril from India — 177 Suppliers Behind a $89.8M Market
India's ramipril export market is supplied by 177 active exporters who collectively shipped $89.8M across 4,977 shipments. MYLAN LABORATORIES LIMITED leads with a 18.9% market share, followed by GENO PHARMACEUTICALS PRIVATE LIMITED and AUROBINDO PHARMA LTD. The top 5 suppliers together control 63.7% of total export value, reflecting a concentrated market structure.
Top Ramipril Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading ramipril exporter from India, holding a 18.9% share of the $89.8M market across 4,977 shipments from 177 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, GENO PHARMACEUTICALS PRIVATE LIMITED, AUROBINDO PHARMA LTD, SANOFI INDIA LIMITED, IND SWIFT LIMITED — collectively control 63.7% of total export value, indicating a moderately concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (18.9%), GENO PHARMACEUTICALS PRIVATE LIMITED (15.6%), AUROBINDO PHARMA LTD (14.8%), SANOFI INDIA LIMITED (7.3%), IND SWIFT LIMITED (7.1%).
Top Ramipril Exporters from India
Ranked by export value · 177 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED RAMIPRIL MYLAN 10MG 90BSRAMIPRIL MYLAN 2.5MG 90BSPHARMACEUTICAL PRODUCTS - RAMIPRIL ZTV 2 | $17.0M | 5 | 18.9% |
| 2 | GENO PHARMACEUTICALS PRIVATE LIMITED RAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL CAPSULES 10MG 2X14'SRAMIPRIL CAPSULES 5MG 2X14'S | $14.0M | 1 | 15.6% |
| 3 | AUROBINDO PHARMA LTD RAMIPRIL MYLAN 10MG 90BSRAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL MYLAN 2.5MG 90BS | $13.3M | 8 | 14.8% |
| 4 | SANOFI INDIA LIMITED RAMIPRIL MYLAN 10MG 90BSRAMIPRIL MYLAN 2.5MG 90BSPHARMACEUTICAL PRODUCTS - RAMIPRIL ZTV 2 | $6.5M | 12 | 7.3% |
| 5 | IND SWIFT LIMITED RAMIPRIL MYLAN 10MG 90BSRAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL MYLAN 2.5MG 90BS | $6.4M | 3 | 7.1% |
| 6 | ZENTIVA PRIVATE LIMITED RAMIPRIL MYLAN 10MG 90BSRAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL MYLAN 2.5MG 90BS | $4.9M | 5 | 5.5% |
| 7 | SUN PHARMACEUTICAL INDUSTRIES LIMITED RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETSPHARMACEUTICAL PRODUCTS - RAMIPRIL HCT 5APO-RAMIPRIL CAP 10MG 500 BTL 47490 / 771313171366-VJ6697 | $4.8M | 5 | 5.3% |
| 8 | MICRO LABS LIMITED RAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL CAPSULES 10MG 2X14'SRAMIPRIL CAPSULES 5MG 2X14'S | $4.2M | 2 | 4.7% |
| 9 | AUROBINDO PHARMA LIMITED RAMIPRIL MYLAN 10MG 90BSRAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL MYLAN 2.5MG 90BS | $4.0M | 8 | 4.5% |
| 10 | LUPIN LIMITED RAMIPRIL CAPSULES 10 MG 500"S NOSRAMIPRIL CAPSULES 5.0 MG RAMIPRIL CAPSULES USP 5 MG 500'SRAMIPRIL CAPSULES 10 MGNOS | $3.6M | 1 | 4.0% |
| 11 | APOTEX RESEARCH PRIVATE LIMITED RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETSAPO-RAMIPRIL CAP 10MG 500 BTL 47490 / 771313171366-VJ6697HARMLESS MEDICINES PHARMA-RAMIPRIL RA | $2.3M | 1 | 2.6% |
| 12 | IPCA LABORATORIES LIMITED RAMIPRIL AND HYDROCHLOROTHIAZIDE TABLETSAPO-RAMIPRIL CAP 10MG 500 BTL 47490 / 771313171366-VJ6697HARMLESS MEDICINES PHARMA-RAMIPRIL RA | $1.3M | 5 | 1.5% |
| 13 | IND-SWIFT LIMITED RAMIPRIL CAPSULES 2.5 MG(RAMIPRIL 2.5MGRAMIPRIL CAPSULES 10MG 2X14'SRAMIPRIL CAPSULES 5MG 2X14'S | $1.2M | 2 | 1.3% |
| 14 | ZYDUS LIFESCIENCES LIMITED RAMIPRIL CAPSULES 10 MG 500"S NOSRAMIPRIL CAPSULES 5.0 MG RAMIPRIL CAPSULES USP 5 MG 500'SRAMIPRIL CAPSULES 10 MGNOS | $999.7K | 1 | 1.1% |
| 15 | AJANTA PHARMA LIMITED RAMIPRIL MYLAN 10MG 90BSRAMIPRIL MYLAN 2.5MG 90BS | $937.2K | 5 | 1.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ramipril exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Approved | Yes | Yes | Multiple | FDA warning letter issued in June 2019 for Pydibhimavaram facility. |
| Mylan Laboratories Limited | Warning Letter, December | Yes | Yes | Not verified | FDA warning letter issued in December 2024 for Indore facility. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Micro Labs Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Lupin Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Ind-Swift Limited | Approved | Yes | Yes | Not verified | No FDA warning letters found. |
| Zydus Lifesciences Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
| Ajanta Pharma Limited | Approved | Yes | Yes | Multiple | No FDA warning letters found. |
TransData Nexus reviewed the regulatory standing of 8 leading Ramipril exporters from India. 7 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ramipril sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. This prominence is supported by a robust ecosystem of pharmaceutical companies, including major players like Dr. Reddy's Laboratories and Aurobindo Pharma. The city's infrastructure, exemplified by the Hyderabad Pharma City project, aims to create the world's largest integrated pharmaceutical hub, further solidifying its status in bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts a significant number of pharmaceutical companies specializing in the production of finished dosage forms. Vadodara, in particular, is home to Alembic Pharmaceuticals, a company with a strong presence in both domestic and international markets. The cluster's emphasis on formulations makes it a strategic location for sourcing finished Ramipril products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai's well-established port facilities and logistical infrastructure facilitate efficient international distribution. The region is home to several pharmaceutical companies with a strong export orientation, making it a pivotal point for the global distribution of medications like Ramipril.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives offered by the government. This zone attracts numerous pharmaceutical companies seeking cost-effective production solutions. While primarily known for domestic supply, the region's growing capabilities make it a potential area for sourcing Ramipril in the future.
5Sourcing Recommendations
- Leverage Hyderabad for API Procurement: Given Hyderabad's dominance in bulk drug production, it is advisable to source Ramipril's active pharmaceutical ingredients (APIs) from manufacturers in this region to ensure quality and cost-effectiveness.
- Utilize Ahmedabad-Vadodara for Finished Formulations: For finished dosage forms of Ramipril, partnering with companies in the Ahmedabad-Vadodara corridor can provide access to high-quality formulations ready for export.
- Optimize Logistics through Mumbai-Thane-Raigad: To streamline international distribution, utilize the export facilities in the Mumbai-Thane-Raigad region, taking advantage of its established infrastructure and proximity to major ports.
- Monitor Baddi-Nalagarh for Emerging Opportunities: Keep an eye on the Baddi-Nalagarh region for potential cost-effective manufacturing options, especially as the area's capabilities continue to expand.
By strategically engaging with these pharmaceutical clusters, companies can enhance their supply chain efficiency and ensure a steady supply of Ramipril for global markets.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ramipril exporters from India
Aurobindo Pharma Limited — Aurobindo Pharma acquires Portugal's Generis for €135 million
Aurobindo Pharma Limited acquired Generis Farmaceutica SA, a Portuguese pharmaceutical company, for €135 million. This acquisition aimed to strengthen Aurobindo's presence in the European market. IMPACT: The acquisition expanded Aurobindo's European footprint, potentially increasing Ramipril exports to European countries.
Impact: The acquisition expanded Aurobindo's European footprint, potentially increasing Ramipril exports to European countries.
Aurobindo Pharma Limited — Aurobindo Pharma to acquire Apotex's businesses in five European countries
Aurobindo Pharma Limited signed a definitive agreement to acquire Apotex's commercial operations in Poland, the Czech Republic, the Netherlands, Spain, and Belgium. This move was intended to enhance Aurobindo's product portfolio and market presence in Europe. IMPACT: The acquisition bolstered Aurobindo's distribution network in Europe, likely facilitating increased Ramipril exports to these markets.
Impact: The acquisition bolstered Aurobindo's distribution network in Europe, likely facilitating increased Ramipril exports to these markets.
Aurobindo Pharma Limited — Aurobindo Pharma acquires four biosimilar products from TL Biopharmaceutical AG
Aurobindo Pharma Limited acquired four biosimilar products from TL Biopharmaceutical AG, marking its entry into the biosimilars segment. This strategic move aimed to diversify Aurobindo's product offerings. IMPACT: While not directly related to Ramipril, the acquisition reflects Aurobindo's strategy to expand its product portfolio, which may indirectly influence its overall export capabilities.
Impact: While not directly related to Ramipril, the acquisition reflects Aurobindo's strategy to expand its product portfolio, which may indirectly influence its overall export capabilities.
Common Questions — Ramipril Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ramipril supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 320 recorded shipments worth $17.0M. GENO PHARMACEUTICALS PRIVATE LIMITED (686 shipments) and AUROBINDO PHARMA LTD (811 shipments) are also established high-volume exporters.
Q How many ramipril manufacturers are there in India?
India has 177 active ramipril exporters with a combined export market of $89.8M across 4,977 shipments to 93 countries. The top 5 suppliers hold 63.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ramipril from India?
Average FOB unit price: $13.25 per unit, ranging from $0.00 to $1296.90. Average shipment value: $18.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 177 verified Indian exporters of Ramipril ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 4,977 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 93 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4,977 Verified Shipments
177 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists